Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.61 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.61 |
| ▸ | HEXA | P06865 | 1/20 | 0.57 |
| ▸ | HEXB | P07686 | 1/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amonafide SCHEMBL5166034 | 0.95 | FTO (0.84) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL5166221 | 0.91 | FTO (0.81) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL5166747 | 0.89 | FTO (0.84) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL5164837 | 0.89 | FTO (0.84) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL5165675 | 0.89 | FTO (0.84) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL1565520 | 0.87 | FTO (0.86) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL6255345 | 0.87 | FTO (1.00) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL29352008 | 0.87 | FTO (1.00) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL27226 | 0.87 | FTO (1.00) | FTOCYP2D6POLBMEN1KMT2A | |
| Amonafide SCHEMBL1566668 | 0.86 | FTO (0.97) | FTOCYP2D6POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499595-B1 | AMONAFIDE SALTS | XANTHUS LIFE SCIENCES INC (CA) | 2007-04-11 | — | — | EP | claimed |
| US-20050113579-A1 | Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof | CHEMGENEX THERAPEUTICS, INC. | 2005-05-26 | — | — | US | claimed |
| EP-1499595-A1 | AMONAFIDE SALTS | Xanthus Life Sciences, Inc. (CA) | 2005-01-26 | — | — | EP | claimed |
| US-20040132763-A1 | Amonafide salts | XANTHUS LIFE SCIENCES, INC. | 2004-07-08 | — | — | US | claimed |
| WO-2003089415-A1 | AMONAFIDE SALTS | XANTHUS LIFE SCIENCES, INC. (CA) | 2003-10-30 | — | — | WO | claimed |
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | disclosed |
| EP-1499595-B1 | AMONAFIDE SALTS | XANTHUS LIFE SCIENCES INC (CA) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067241-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | MYC, NME2, TP53 | FTO 3395/4885CYP2D6 358/4885POLB 1283/4885 |
| US-20040132763-A1 | Amonafide salts | OR10J3, NR4A1, OGFR | FTO 974/4885CYP2D6 135/4885POLB 4068/4885 |
| US-20050113579-A1 | Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof | NME4, MFN2, NDUFAB1 | FTO 1262/4885CYP2D6 103/4885POLB 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.